NCT00905021View on ClinicalTrials.gov

Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

January 31, 2011

Study Completion Date

February 29, 2012

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Exemestane

Exemestane 25 mg by mouth every day.

DRUG

Sutent

Sunitinib 37.5 mg by mouth every day.

Trial Locations (1)

77030

Baylor College of Medicine, Lester and Sue Smith Breast Center, Houston

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Baylor Breast Care Center

OTHER